SequelSEC

Tenaya Therapeutics, Inc. TNYA

Biological Products, (No Diagnostic Substances) · CIK 0001858848 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$93.33M
Fiscal year ended 2025-12-31
Free cash flow
-$68.88M
Fiscal year ended 2025-12-31

Tenaya Therapeutics, Inc. (TNYA) reported net income of -$90.60M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Tenaya Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Tenaya Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$93.33M-$115.95M-$131.19M-$125.62M-$72.81M-$38.91M
Net income-$90.60M-$111.13M-$124.08M-$123.66M-$72.72M-$38.40M
Research & development$68.61M$86.74M$98.04M$94.54M$54.39M$31.10M
Weighted-average diluted sharesshares 152.97Mshares 84.82Mshares 73.79Mshares 44.82Mshares 17.73MUnavailable
Pretax income-$90.60M-$111.13M-$124.08M-$123.66M-$72.72M-$38.40M
Income tax expense$0$0$0$0$0$0
Diluted EPS$-0.59$-1.31$-1.68$-2.76$-4.10Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$24.72M$29.21M$33.16M$31.08M$18.41M$7.81M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Tenaya Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$100.55M$4.32M$45.68M$95.27M$38.13M$128.54M
Total assets$146.92M$119.94M$170.52M$278.94M$314.19M$148.16M
Current assets$105.59M$67.38M$111.58M$193.75M$255.36M$129.96M
Total liabilities$23.66M$27.09M$31.09M$35.57M$35.66M$8.72M
Current liabilities$15.44M$15.98M$22.73M$24.25M$21.77M$5.04M
Total equity incl. NCI$123.26M$92.85M$139.42M$243.38M$278.53M-$81.32M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailable$220.75M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$3.58M$5.16M$5.63M$9.58M$10.72M$1.02M

Cash flow

Tenaya Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$68.26M-$90.50M-$102.07M-$104.42M-$60.81M-$35.45M
Capital expenditures$618.00K$1.02M$1.24M$20.63M$25.12M$9.76M
Investing cash flow$56.08M$1.13M$48.72M$83.65M-$238.56M-$7.01M
Financing cash flow$108.40M$47.75M$4.05M$77.77M$208.97M$147.27M
Net change in cash$96.22M-$41.62M-$49.31M$57.00M-$90.41M$104.81M
Stock-based compensation$13.05M$16.50M$15.31M$11.47M$2.95M$741.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable$13.00K$1.00K
Depreciation & amortization$8.44M$8.47M$8.69M$6.47M$2.96M$2.48M

Derived

Tenaya Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flow-$68.88M-$91.53M-$103.31M-$125.05M-$85.93M-$45.21M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio6.84x4.22x4.91x7.99x11.73x25.78x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TNYA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-03-11View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-07View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.